Abstract
Alignment Healthcare, Inc. will release third-quarter 2026 results on October 29, 2026, Post-Mkt; investors look for revenue of 1.31 billion US dollars and adjusted EPS of -0.03, while EBIT is projected at 10.35 million, and sentiment is framed by recent CMS Star Ratings headlines and ongoing execution against 2026 guidance.
Market Forecast
Consensus for the current quarter points to revenue of 1.31 billion US dollars, up 33.79% year over year, adjusted EPS of -0.03 improving 57.56% year over year, and EBIT of 10.35 million up 195.07% year over year. There is no formal company forecast for gross margin or net margin this quarter, but the market expects operating leverage to moderate versus the unusually strong second quarter print.
The main business remains premium-based revenue with a focus on Medicare Advantage plans, and the outlook centers on sustaining top-line growth while balancing medical cost trends and quality initiatives. The most promising revenue driver continues to be earned premiums (1.33 billion US dollars last quarter, representing 99.33% of total revenue), with overall company revenue up 31.55% year over year in that period.
Last Quarter Review
The previous quarter delivered revenue of 1.34 billion US dollars, a gross profit margin of 13.55%, GAAP net income attributable to the parent company of 36.56 million US dollars, a net profit margin of 2.74%, and adjusted EPS of 0.17, up 142.86% year over year.
A key highlight was EBIT of 42.10 million, up 85.07% year over year, as operating scale improved and revenue outperformed consensus by 25.68 million US dollars.
The main business was highly concentrated in earned premiums at 1.33 billion US dollars (99.33% of total revenue), with overall company revenue expanding 31.55% year over year as membership and plan economics supported growth.
Current Quarter Outlook
Core premiums and profitability cadence
For the third quarter, Alignment Healthcare, Inc. is modeled to post 1.31 billion US dollars of revenue, up 33.79% year over year, alongside an adjusted EPS loss of -0.03 that still represents a 57.56% year-over-year improvement and an EBIT of 10.35 million, up 195.07% year over year. This setup implies a sequential moderation in profitability after a seasonally and operationally strong second quarter, consistent with intra-year medical cost patterns and ongoing investments to support growth and quality. The central question for the print is whether medical cost trends and risk-adjustment capture remain on track to keep the full-year 2026 revenue outlook intact while protecting unit economics in a quarter that typically exhibits less operating leverage than the spring period.
Gross profit margin and net profit margin were 13.55% and 2.74% last quarter, respectively; while there is no explicit margin guide for the third quarter, investors will parse commentary on utilization, unit cost inflation, and any offsets from care management and network initiatives. Sustained revenue growth at roughly one-third year-over-year combined with narrower losses on an EPS basis should help the company demonstrate a disciplined path through the second half, even if the absolute margin profile softens from the second quarter peak. The quality and mix of growth—particularly retention of profitable cohorts and controlled acquisition cost during the Annual Election Period—will be scrutinized as early read-throughs for fourth quarter and the 2027 plan year setup.
A secondary lens for this quarter will be operating cash needs and any signs of working-capital strain. Even absent formal cash-flow disclosure in the consensus figures, investors often triangulate from medical claims payable trends and premium receivables to infer seasonality and utilization normalization following periods of elevated activity. A steady medical cost trend and stable reserve development would reinforce the improving EBIT trajectory implied by the forecast.
Most promising growth driver: California platform expansion and provider alignment
Strategic expansions across California and strengthened provider partnerships form a visible growth vector into the next plan year cycle and beyond. Recent updates included plans to expand to new California counties and deepen relationships with notable provider groups, including Astrana Health and Hoag, which together should widen in-network access for Medicare Advantage members and support more coordinated care. While the revenue impact is not expected to materially land in the third quarter results, these initiatives underpin membership growth prospects, risk score capture, and care management effectiveness—key ingredients for sustaining revenue compounding and improving medical margin durability over time.
The company’s earned premiums of 1.33 billion US dollars last quarter, representing 99.33% of total revenue, underscore the importance of footprint depth and network quality in its flagship market. California has been both a scale and capability center, and the announced provider arrangement with Astrana Health is designed to streamline referrals, improve access to specialty care, and reduce leakage—factors that can translate into better utilization control and member experience metrics. As these relationships mature, the payoff typically manifests in improved retention, higher net promoter scores, and a better balance between revenue per member and medical loss rates, all of which reinforce revenue growth and margin stability.
Key stock-price swing factor this quarter: CMS Star Ratings overhang and guidance credibility
The recent release of 2027 CMS Star Ratings introduced a near-term sentiment overhang after one California HMO contract—historically significant to the book—was reported at 3.5 stars, while six of seven eligible contracts achieved at least four stars, with three at 4.5 stars. The market reaction, including a sharp move in managed care stocks and a notable decline in Alignment shares, reflects concern about future quality bonus payments and competitive positioning for the affected contract. While the financial impact of the 2027 Star Ratings is a mid-cycle consideration rather than a third-quarter P&L event, investors will look for management’s commentary on remediation timelines, appeals, and operational steps designed to restore that contract to four stars or better.
Against this backdrop, the credibility and achievability of the 2026 full-year revenue outlook—previously communicated as a range of approximately 5.20 billion to 5.23 billion US dollars—will be an anchor for the stock into year-end. If the company reiterates its annual guide while tracking toward the third-quarter consensus profile on revenue and an improving EBIT line, the market could recalibrate the near-term risk discount tied to the ratings news. Conversely, any hint of accelerated medical cost pressure, stickiness in utilization, or a deterioration in unit economics would amplify the ratings overhang and keep the stock sensitive to updated views from the sell side.
Another swing factor is the Annual Election Period execution and the early visibility that management can offer into fourth-quarter membership trends. A disciplined acquisition strategy that favors quality and profitability over sheer volume can help counterbalance the anxiety stemming from the single-contract downgrade. Given that six of seven eligible contracts received four stars or higher, there is room for the company to emphasize strengths within its broader portfolio, which can support marketing effectiveness and member retention through the selling season.
Analyst Opinions
Bullish opinions dominate among recently published directional calls, with 100% of explicit buy/sell recommendations skewing positive over the review window, and neutral/hold stances rounding out the balance. KeyBanc’s Matthew Gillmor reiterated a Buy rating and a 12.00 US dollars price target, citing confidence in the growth and profitability path implied by current-quarter forecasts—revenue up 33.79% year over year, EBIT positive and ramping, and EPS loss narrowing by 57.56% year over year. J.P. Morgan’s team maintained a Buy rating with a 22.00 US dollars target earlier in the year, aligning with a broader constructive stance that emphasizes the durability of top-line expansion and the potential for operating leverage as the company scales.
Supportive analysts point to three areas they will watch on October 29, 2026, Post-Mkt: first, confirmation that revenue remains on a mid-30% year-over-year trajectory with stable unit economics; second, signals that medical cost trends are consistent with the second quarter framework and do not suggest adverse selection or unexpected utilization spikes; and third, a credible remediation plan around the 2027 Star Ratings that preserves the medium-term quality bonus pathway. They argue that six of seven eligible contracts earning at least four stars provides a foundation to compete effectively during the selling season, particularly where provider access has been expanded and care coordination can be showcased.
The bullish camp also highlights the second quarter as a proof point that scale is translating into better earnings power, with 42.10 million US dollars of EBIT, 36.56 million US dollars in GAAP net income attributable to the parent company, and adjusted EPS of 0.17. Although third-quarter consensus embeds lower profitability than the second quarter, these analysts view the sequential step down as a function of seasonality and prudent reinvestment, rather than deterioration in fundamentals. On their math, the swing from a second-quarter profit to a modest third-quarter EPS loss is consistent with historical intra-year patterns for Medicare Advantage operators and should not overshadow the year-over-year acceleration in revenue and EBIT improvements.
Where the bullish view leans cautious is in acknowledging the headline sensitivity surrounding the CMS Star Ratings. The downgrade of the California HMO contract to 3.5 stars for the 2027 ratings cycle sparked a strong stock reaction, and analysts recognize the need for concrete milestones to validate the remediation path. However, they assess the issue as addressable over the medium term, and they note that the broader contract set achieved desirable ratings thresholds that support competitive positioning, including several at 4.5 stars. In their framing, steady execution in the third quarter—hitting revenue, demonstrating positive EBIT, and contextualizing the ratings process—can help stabilize sentiment.
Looking forward, bullish analysts see provider network enhancements, including the arrangement with Astrana Health and ties to Hoag, as reinforcing the company’s core strengths in its primary market. While these agreements are not expected to meaningfully shift third-quarter reported results, they are viewed as catalysts for better medical management, more predictable utilization, and sustainable growth into the next plan year. As such, supportive institutions tend to anchor their price targets on a combination of revenue visibility, improving operating metrics, and a belief that quality metrics can be restored, rather than on a thesis that relies solely on near-term margin expansion.
In sum, the majority view heading into the October 29, 2026, Post-Mkt print is constructive: revenue is expected to rise 33.79% year over year to 1.31 billion US dollars, EBIT is forecast to be positive at 10.35 million with triple-digit year-over-year growth, and adjusted EPS is modeled to improve markedly on a year-over-year basis despite a small loss. The market remains attentive to management’s commentary on utilization, guidance, and Star Ratings remediation, but the dominant stance among named analysts is that the company’s growth and execution framework remains intact and investable under current assumptions.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments